#1 Clinical Trials Search in Europe

DNL593

A promising clinical trial is underway to investigate DNL593, a potential treatment for frontotemporal dementia (FTD). This Phase 1/2 study aims to evaluate how safe DNL593 is, how well it’s tolerated, and how it works in the body. The trial involves both healthy participants and those diagnosed with frontotemporal dementia caused by GRN mutations (FTD-GRN). The study is being conducted in multiple stages, starting with single doses in healthy individuals before moving to multiple doses in FTD patients over 25 weeks, with an optional 18-month extension period. This research represents an important step in developing new treatment options for this challenging form of dementia.

Table of Contents

What is DNL593?

DNL593 is an investigational drug being studied as a potential treatment for Frontotemporal Dementia (FTD), specifically for patients with a genetic form of the disease known as FTD-GRN[1]. This medication is currently in clinical trials to evaluate how safe it is, how well the body processes it, and what effects it has on the disease.

The drug is being administered in different dosages depending on whether it’s being given to healthy volunteers or patients with FTD. While still in the research phase, DNL593 represents an important step in developing treatments for this challenging neurological condition[1].

What is Frontotemporal Dementia (FTD)?

Frontotemporal Dementia is a type of dementia that primarily affects the frontal and temporal lobes of the brain, which are associated with personality, behavior, and language[1]. Unlike Alzheimer’s disease, which typically affects memory first, FTD often begins with changes in personality, behavior, or difficulties with speech and language.

The specific type being targeted in this study, FTD-GRN, refers to frontotemporal dementia caused by mutations in the progranulin (GRN) gene. This genetic form of FTD has specific characteristics that make it a distinct target for specialized treatments like DNL593[1].

Clinical Study Details

The clinical trial for DNL593 is identified as NCT05262023 and is described as a “Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study”[1]. Let’s break down what these terms mean:

  • Phase 1/2: This indicates an early-stage clinical trial designed to assess both safety (Phase 1) and preliminary effectiveness (Phase 2).
  • Multicenter: The study is being conducted at multiple medical facilities.
  • Randomized: Participants are randomly assigned to either receive DNL593 or a placebo.
  • Placebo-controlled: Some participants receive an inactive substance (placebo) instead of the actual drug to provide a comparison group.
  • Double-blind: Neither the participants nor the researchers know who is receiving the actual drug versus the placebo during the study.

This rigorous study design helps ensure that the results are reliable and not influenced by bias or expectations[1].

Study Structure

The clinical trial for DNL593 is organized into three main parts[1]:

  1. Part A: This initial phase involves healthy volunteers who receive single doses of DNL593. The purpose is to evaluate the safety, tolerability, and how the body processes the drug (pharmacokinetics or PK) in people without the disease. This helps establish basic safety information before testing in patients.
  2. Part B: This phase involves participants who have been diagnosed with frontotemporal dementia. These patients receive multiple doses of DNL593 over a 25-week period. The study will continue to assess safety but will also begin to look at how the drug affects the disease.
  3. Part C: This is an optional 18-month open-label extension (OLE) period available to all participants who complete Part B. In an open-label extension, all participants receive the active drug (no placebo), and everyone knows they are receiving the actual treatment.

This structured approach allows researchers to carefully monitor both the short-term and long-term effects of DNL593[1].

Safety Evaluation

A primary goal of the study is to determine if DNL593 is safe for patients. Researchers are tracking several safety measures[1]:

  • Treatment-emergent adverse events (TEAEs): Any new medical problems that appear after starting treatment
  • Changes in laboratory test results
  • Changes in vital signs, including:
    • Blood pressure
    • Heart rate
    • Breathing rate
    • Body temperature
  • Changes in electrocardiogram (ECG) results, which measure the electrical activity of the heart
  • Physical and neurological examination findings
  • Changes in scores on the Columbia-Suicide Severity Rating Scale (C-SSRS), which monitors for potential suicidal thoughts or behaviors

These comprehensive safety assessments help ensure that any risks associated with DNL593 are identified quickly[1].

Effectiveness Measures

In addition to safety, the study is examining how DNL593 works in the body and what effects it has on the disease[1]. Key measurements include:

  • Pharmacokinetics (PK): How the body processes the drug, including:
    • Maximum concentration in the blood (Cmax)
    • How long it takes to reach maximum concentration (tmax)
    • How long the drug stays in the system (AUC – Area Under the Curve)
    • How long it takes for the body to eliminate half of the drug (t1/2 or half-life)
  • Concentration in cerebrospinal fluid (CSF): This measures how well the drug reaches the brain and spinal cord
  • CSF:serum concentration ratio: This indicates how effectively the drug crosses from the bloodstream into the central nervous system
  • Changes in plasma NfL (Neurofilament Light Chain), a biomarker that can indicate damage to nerve cells

These measurements help researchers understand if DNL593 is reaching its intended targets and having the desired biological effects[1].

Implications for Patients

For patients with frontotemporal dementia, especially those with the FTD-GRN genetic variant, the development of DNL593 represents an important research effort[1]. Currently, there are limited treatment options specifically designed for FTD, and most existing treatments only address symptoms rather than targeting the underlying disease process.

If successful, this research could lead to a new treatment option for FTD patients. However, it’s important to understand that the drug is still in clinical trials, and it will take time to determine its safety and effectiveness. The comprehensive design of this study, with its three-part structure and extensive monitoring, demonstrates the thorough approach being taken to evaluate this potential new therapy[1].

Patients interested in frontotemporal dementia treatments should discuss with their healthcare providers the latest developments in this field and whether participating in clinical trials might be appropriate for their specific situation.

Study Aspect Details
Study Type Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study
Drug Being Tested DNL593
Target Condition Frontotemporal Dementia (FTD), specifically FTD-GRN
Study Structure – Part A: Single doses in healthy participants
– Part B: Multiple doses in FTD patients over 25 weeks
– Part C: Optional 18-month open-label extension
Participant Groups – Healthy participants (receiving DNL593 or placebo)
– FTD patients (receiving DNL593 or placebo)
Primary Outcomes – Safety assessments
– Tolerability measures
– Vital sign changes
– Laboratory results
– ECG findings
Secondary Outcomes – How the drug moves through the body (PK parameters)
– How much drug reaches the brain (CSF levels)
– Changes in blood biomarkers (NfL)

FAQ

  • What is DNL593 and what is it being studied for? DNL593 is an investigational drug being studied as a potential treatment for frontotemporal dementia (FTD), specifically in patients with a genetic form of the disease. The clinical trial is examining if DNL593 is safe, how well patients tolerate it, how it moves through the body (pharmacokinetics), and what effects it has (pharmacodynamics).
  • How is the clinical trial for DNL593 structured? The trial has multiple parts: Part A tests single doses in healthy participants to assess safety. Part B evaluates multiple doses in people with frontotemporal dementia over 25 weeks. Part C is an optional 18-month open-label extension period for participants who complete Part B, where all participants receive the active drug (not placebo).
  • What are the main safety measures being tracked in the DNL593 trial? The trial is carefully monitoring several safety aspects, including: side effects that emerge during treatment, changes in laboratory test results, vital signs (blood pressure, heart rate, breathing rate, body temperature), heart activity through ECG readings, physical and neurological exam findings, and suicide risk assessment using a standardized scale called C-SSRS.
  • How will researchers know if DNL593 is working properly in the body? Researchers are measuring several aspects of how DNL593 works in the body, including how much of the drug appears in the blood, how long it takes to reach maximum concentration, how long it stays in the body, and importantly, whether it reaches the brain by measuring levels in the cerebrospinal fluid (the fluid surrounding the brain and spinal cord). They're also tracking changes in a blood marker called NfL (neurofilament light chain), which can indicate effects on the nervous system.
  • Is this a blinded study, and what does that mean for participants? Yes, Parts A and B are randomized, double-blind, and placebo-controlled. This means that participants are randomly assigned to receive either DNL593 or a placebo (a substance with no active drug), and neither the participants nor the researchers directly interacting with them know who received which. This design helps prevent bias in evaluating the results. However, Part C (the extension period) is open-label, meaning all participants receive the active drug and everyone knows what they're getting.

Ongoing Clinical Trials on DNL593

  • Study on the Safety and Effects of DNL593 for Patients with Frontotemporal Dementia

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Italy The Netherlands Portugal +1

Glossary

  • Frontotemporal Dementia (FTD): A type of dementia that affects the frontal and temporal lobes of the brain, causing changes in personality, behavior, and language abilities. The specific form studied in this trial (FTD-GRN) is caused by mutations in the progranulin gene.
  • Phase 1/2 Clinical Trial: An early stage of clinical research that combines elements of both Phase 1 (which focuses primarily on safety in a small group of people) and Phase 2 (which begins to assess effectiveness while continuing to monitor safety in a larger group).
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated. In simple terms, it's what the body does to the drug.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including the biological and physiological effects. In simple terms, it's what the drug does to the body.
  • Randomized: A process where participants are assigned by chance (like flipping a coin) to different treatment groups, which helps prevent bias in research studies.
  • Placebo-Controlled: A study design where some participants receive an inactive substance (placebo) that looks like the real treatment but has no active ingredients. This helps determine if improvements are due to the actual treatment or other factors.
  • Double-Blind: A study design where neither the participants nor the researchers directly interacting with them know who is receiving the actual treatment and who is receiving the placebo.
  • Open-Label Extension (OLE): A continuation phase of a clinical trial where all participants receive the active treatment (not placebo) and everyone knows what they're receiving. This often follows the main blinded portion of a trial.
  • Treatment-Emergent Adverse Events (TEAEs): Side effects or unwanted experiences that begin or worsen after starting a treatment in a clinical trial.
  • Cerebrospinal Fluid (CSF): The clear fluid that surrounds the brain and spinal cord. Analyzing this fluid can help researchers determine if a drug reaches the brain.
  • Neurofilament Light Chain (NfL): A protein released when neurons (brain cells) are damaged. Measuring levels of this protein in blood can help track the progression of neurodegenerative diseases and potentially show if treatments are helping.
  • Cmax: The maximum concentration of a drug in the blood after it is administered, which helps determine how much of the drug reaches the bloodstream.
  • Tmax: The time it takes for a drug to reach its maximum concentration in the blood, which helps determine how quickly the drug is absorbed.
  • Half-life (t1/2): The time it takes for the concentration of a drug in the body to decrease by half, which helps determine how long the drug stays in the system.
  • Area Under the Curve (AUC): A measurement of the total amount of drug in the bloodstream over time, which helps determine overall exposure to the drug.
  • Columbia-Suicide Severity Rating Scale (C-SSRS): A standardized tool used to assess suicide risk in clinical trials and other settings.

References